Sanofi plans to apply for listing of isatuximab by the end of this year

In the icaria-mm study, 307 patients with relapsed and refractory multiple myeloma who had previously received more than two therapies including lenalidomide and / or a proteasome inhibitor were randomly divided into two groups and given standard treatment (pomalidomide + low dose dexamethasone) or standard treatment + isatuximab< br / > the results showed that the PFS was prolonged by 5 months (11.53 vs 6.47 months) and the risk of disease progression and death was reduced by 40% and the orr was also significantly increased (60% vs 35%) compared with the control groupIn addition, the time to receive the next treatment was significantly longer (immature vs9.1 months)< br / > in terms of safety, 86.8% and 70.5% of the patients in isatuximab + pomadolamine + dexamethasone group and pomadolamine + dexamethasone group had more than 3-level adverse events, 7.2% and 12.8% of the patients stopped treatment due to adverse events, and 7.9% and 9.4% of the patients died due to adverse events, respectivelyThe incidence of infection above level 3 was 42.8% and 30.2% respectivelyThe number of neutrophils above grade 3 was 84.9% and 70.1%, respectively< br / > darzalex (daratumumab) is the only monoclonal antibody of CD38 currently on the marketIt was approved in November 2015, and its global sales reached US $2.025 billion in 2018< br / > original title: isatuximab reduces the risk of progression or death by 40% in the treatment of relapsed refractory multiple myeloma